Clinical trialNCT06726148RecruitingPhase 1/PHASE2Interventional

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

SponsorNovartis PharmaceuticalsEnrollment280Advanced CCNE1-amplified Solid TumorsAdvanced HR+/HER2- Breast CancerExtensive-stage Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
Clayton, Victoria, Australia
Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia
Recruiting

Canada

Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting

China

Novartis Investigative Site
Nanjing, Jiangsu, China
Recruiting
Novartis Investigative Site
Xian, Shanxi, China
Recruiting

Czechia

Novartis Investigative Site
Brno, Czechia
Recruiting

Denmark

Novartis Investigative Site
Copenhagen, Denmark
Recruiting
Novartis Investigative Site
Odense C, Denmark
Recruiting

France

Novartis Investigative Site
Bordeaux, France
Recruiting
Novartis Investigative Site
Saint-Herblain, France
Recruiting

Germany

Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Recruiting
Novartis Investigative Site
Heidelberg, Germany
Recruiting
Novartis Investigative Site
Ulm, Germany
Recruiting

Israel

Novartis Investigative Site
Haifa, Israel
Recruiting
Novartis Investigative Site
Tel Aviv, Israel
Recruiting

Italy

Novartis Investigative Site
Modena, MO, Italy
Recruiting
Novartis Investigative Site
Milan, Italy
Recruiting

Japan

Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Recruiting

Singapore

Novartis Investigative Site
Singapore, Singapore
Recruiting

South Korea

Novartis Investigative Site
Seoul, Seoul, South Korea
Recruiting

Spain

Novartis Investigative Site
Barcelona, Spain
Recruiting
Novartis Investigative Site
Barcelona, Spain
Recruiting

Taiwan

Novartis Investigative Site
Tainan, Taiwan
Recruiting

United Kingdom

Novartis Investigative Site
London, Oxford, United Kingdom
Recruiting

United States

University of California la
Los Angeles, California, United States
Saeed Sadeghi
Recruiting
Florida Cancer Specialists
Fort Myers, Florida, United States
Manish Patel
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Antonio Giordano
Recruiting
Wa Uni School of Med
St Louis, Missouri, United States
Cynthia Ma
Recruiting
Memorial Sloan Kettering
New York, New York, United States
Komal Jhaveri
Recruiting
Scri Oncology Partners
Nashville, Tennessee, United States
Erika Paige Hamilton →
Recruiting
Md Anderson Cancer Center Uni of Te
Houston, Texas, United States
Timothy Yap
Recruiting
Fred Hutch Cancer Research
Seattle, Washington, United States
Sara Hurvitz
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ECI830Fulvestrant →Ribociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Apr 2025
Primary completion: 25 Sept 2028
Completion: 25 Sept 2028
Last update posted: 13 Jul 2026
Registered enrollment: 280
Registry id: NCT06726148

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-517281-42

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.